SDI-118

DRUG3 trials

Sponsors

Syndesi Therapeutics, AbbVie

Conditions

Cognitive DeclineCognitive DisordersDepression in Remission

Phase 1

A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SDI-118 in Elderly Male and Female Study Participants With Cognitive Decline

TerminatedNCT05199142

Syndesi TherapeuticsCognitive Decline

Start: 2021-09-23End: 2022-03-11Updated: 2022-04-22

A Study of SDI-118 in Participants in Remission From Depression

WithdrawnNCT05212116

Syndesi TherapeuticsDepression in Remission

Start: 2021-09-16End: 2022-03-11Updated: 2022-04-22

A Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects Including an Assessment of Receptor Occupancy and Food Effect

CompletedNCT05486195

AbbVieCognitive Disorders

Start: 2019-03-14End: 2020-03-11Updated: 2022-08-03

Related Papers

SDI-118, a novel procognitive SV2A modulator: First-in-human randomized controlled trial including PET/fMRI assessment of target engagement

Frontiers in Pharmacology2023-01-179 citations